title: Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.
abstract: Forty-two medical centers from throughout the United States participating in a longitudinal surveillance program were asked to submit 100 consecutive Staphylococcus aureus isolates during July to December 2011. Susceptibility testing using CLSI broth microdilution and mecA detection by PCR analysis was performed on the 4,131 isolates collected. Methods employing Etest glycopeptide resistance detection (GRD; bioMérieux) and brain heart infusion agar containing 4 μg/ml vancomycin (BHIV) were used to screen methicillin-resistant S. aureus (MRSA) isolates for heterogeneous intermediate-level resistance to vancomycin (hVISA). Isolates with positive hVISA screen results were confirmed by population analysis profiling-area under the curve (PAP-AUC) determinations. The genetic relatedness of hVISA, ceftaroline-nonsusceptible, or high-level (HL) mupirocin resistance MRSA isolates was assessed by pulsed-field gel electrophoresis (PFGE). Among 2,093 MRSA isolates, the hVISA screen results were positive with 47 isolates by Etest GRD and 30 isolates by BHIV agar screen. Twenty-five of the GRD- or BHIV screen-positive isolates were confirmed as hVISA by PAP-AUC testing. Results of the current study were compared to results obtained from prior surveillance performed in 2009. The prevalence of hVISA among MRSA isolates was higher in 2011 than in 2009 (1.2% versus 0.4%, P = 0.003), especially for isolates with a vancomycin MIC of 2 (45.4% versus 14.3%, P = 0.01). The overall rate of ceftaroline susceptibility in the current study was 99.4% (one hVISA isolate had an intermediate ceftaroline MIC). HL mupirocin resistance increased from 2.2% in 2009 to 3.2% in 2011 (P = 0.006). Although overall rates of hVISA and HL mupirocin resistance are low, they have increased since 2009.
authors.affiliation: Cleveland Clinic, Cleveland, Ohio, USA.
authors.forename: Sandra S
authors.initials: SS
authors.lastname: Richter
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Diekema
authors.forename: Kristopher P
authors.initials: KP
authors.lastname: Heilmann
authors.forename: Cassie L
authors.initials: CL
authors.lastname: Dohrn
authors.forename: Emily K
authors.initials: EK
authors.lastname: Crispell
authors.forename: Fathollah
authors.initials: F
authors.lastname: Riahi
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: McDanel
authors.forename: Sarah W
authors.initials: SW
authors.lastname: Satola
authors.forename: Gary V
authors.initials: GV
authors.lastname: Doern
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D016521:Electrophoresis, Gel, Pulsed-Field; D062665:Epidemiological Monitoring; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D008826:Microbial Sensitivity Tests; D016712:Mupirocin / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000453:epidemiology* / Q000382:microbiology; D014481:United States / Q000453:epidemiology; D014640:Vancomycin / Q000627:therapeutic use*; D020713:Vancomycin Resistance; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D016712:Mupirocin; D014640:Vancomycin; D000097583:Ceftaroline